Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KRYS
stocks logo

KRYS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
105.97M
+16.27%
1.474
-3.68%
120.26M
+36.37%
1.520
+26.67%
138.92M
+44.64%
1.938
+50.19%
Estimates Revision
The market is revising Upward the revenue expectations for Krystal Biotech, Inc. (KRYS) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 47.71%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+24.45%
In Past 3 Month
Stock Price
Go Up
up Image
+47.71%
In Past 3 Month
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 221.960
sliders
Low
198.00
Averages
221.00
High
255.00
Current: 221.960
sliders
Low
198.00
Averages
221.00
High
255.00
Citi
Yigal Nochomovitz
Neutral
maintain
$166 -> $198
2025-11-04
Reason
Citi
Yigal Nochomovitz
Price Target
$166 -> $198
2025-11-04
maintain
Neutral
Reason
Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $198 from $166 and keeps a Neutral rating on the shares following the Q3 report. Citi views the shares as fairly valued but believes Krystal is well positioned into its 2026 pipeline readouts.
Clear Street
Buy
maintain
$212 -> $217
2025-11-03
Reason
Clear Street
Price Target
$212 -> $217
2025-11-03
maintain
Buy
Reason
Clear Street raised the firm's price target on Krystal Biotech to $217 from $212 and keeps a Buy rating on the shares after Krystal reported Q3 results. The firm, which see Vyjuvek as having steadied in the U.S. and near term growth to be driven by international launches, increased its FY25 revenue estimate to $383M and decreased its expense estimates in line with guidance.
Chardan
Buy
maintain
$216 -> $220
2025-11-03
Reason
Chardan
Price Target
$216 -> $220
2025-11-03
maintain
Buy
Reason
Chardan raised the firm's price target on Krystal Biotech to $220 from $216 and keeps a Buy rating on the shares. The company's Q3 net Vyjuvek revenue topped estimates as results included a contribution from the recent launch in Germany, the analyst tells investors in a research note. Krystal has also reported an improved gross margin of 96% and "stable" gross-to-net ratio with previous quarters, the firm added.
BofA
BofA
NULL -> Buy
maintain
$182 -> $255
2025-10-17
Reason
BofA
BofA
Price Target
$182 -> $255
2025-10-17
maintain
NULL -> Buy
Reason
BofA raised the firm's price target on Krystal Biotech to $255 from $182 and keeps a Buy rating on the shares. The firm, which continues to like Vyjuvek, Krystal's drug treating the rare skin condition dystrophic epidermolysis bullosa, also adjusts its pipeline and platform contribution estimates to add standalone revenue builds for KB801 and KB803 as it believes near-term pipeline data could be "value unlocking."
Guggenheim
Debjit Chattopadhyay
NULL -> Buy
maintain
$189 -> $224
2025-10-17
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$189 -> $224
2025-10-17
maintain
NULL -> Buy
Reason
Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Krystal Biotech to $224 from $189 and keeps a Buy rating on the shares. The firm, which anticipates Krystal will be able to return to about 50 total new PSF per quarter during Q2, anticipates an equilibrium between efficacy-driven drop in compliance and new patient adds by year-end 2025, the analyst tells investors in a preview.
Chardan
Buy
maintain
$219 -> $216
2025-08-22
Reason
Chardan
Price Target
$219 -> $216
2025-08-22
maintain
Buy
Reason
Chardan lowered the firm's price target on Krystal Biotech to $216 from $219 and keeps a Buy rating on the shares after the company announced it will be prioritizing the development of inhaled KB707 for the treatment of non-small cell lung cancer and de-prioritizing the development of KB707 in the intratumoral setting. In conjunction with the prioritization of inhaled KB707, Krystal has paused enrollment in the intratumoral OPAL-1 trial, notes the analyst, who expects additional color on the go forward plan and an update on FDA interactions with Q3 earnings due in November.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Krystal Biotech Inc (KRYS.O) is 31.41, compared to its 5-year average forward P/E of -15.21. For a more detailed relative valuation and DCF analysis to assess Krystal Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.21
Current PE
31.41
Overvalued PE
51.66
Undervalued PE
-82.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.45
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
58.98
Undervalued EV/EBITDA
-34.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
164.75
Current PS
0.00
Overvalued PS
744.59
Undervalued PS
-415.08
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KRYS News & Events

Events Timeline

(ET)
2025-11-03
07:04:11
Krystal Biotech Announces Q3 Earnings Per Share of $2.66, Exceeding Consensus Estimate of $1.12
select
2025-10-14 (ET)
2025-10-14
08:03:19
Krystal Biotech Receives FDA Designation for HSV-1 Viral Vector Platform Technology
select
2025-09-15 (ET)
2025-09-15
08:15:14
Krystal Biotech Receives FDA Approval for Updated VYJUVEK Label
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26Globenewswire
Krystal Biotech CEO to Participate in 8th Annual Evercore Healthcare Conference
  • Conference Participation: Krystal Biotech will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami, where CEO Krish S. Krishnan will engage in a fireside chat at 10:00 am, showcasing the company's leadership in gene therapy.
  • Investor Meetings: Throughout the day, Krish S. Krishnan will host multiple investor meetings aimed at strengthening relationships with investors and enhancing the company's visibility in the capital markets, potentially paving the way for future financing opportunities.
  • Webcast Availability: The company will provide a webcast of the presentation on its website, ensuring that investors unable to attend in person can access real-time information, thereby enhancing transparency and attracting more attention.
  • Product Background: Krystal Biotech's first commercial product, VYJUVEK®, is the world's first redosable gene therapy approved in the U.S., Europe, and Japan, demonstrating the company's potential in addressing high unmet medical needs.
[object Object]
Preview
8.0
11-05NASDAQ.COM
Significant Options Activity on Tuesday: ANDE, KRYS, CRWD

  • Krystal Biotech Inc Options Activity: Krystal Biotech Inc (KRYS) experienced options trading volume of 2,033 contracts, equating to about 203,300 underlying shares, with significant activity in the $210 strike call option expiring December 19, 2025.

  • CrowdStrike Holdings Inc Options Activity: CrowdStrike Holdings Inc (CRWD) saw a higher options trading volume of 16,891 contracts, representing approximately 1.7 million underlying shares, with notable trading in the $530 strike put option expiring November 07, 2025.

  • Trading Volume Comparison: Both KRYS and CRWD had options trading volumes that accounted for around 71% of their respective average daily trading volumes over the past month.

  • Further Information: For additional details on available options expirations for ANDE, KRYS, or CRWD, users can visit StockOptionsChannel.com.

[object Object]
Preview
9.5
11-03NASDAQ.COM
Krystal Biotech (KRYS) Third Quarter 2025 Earnings Report Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Krystal Biotech Inc (KRYS) stock price today?

The current price of KRYS is 221.96 USD — it has increased 2.07 % in the last trading day.

arrow icon

What is Krystal Biotech Inc (KRYS)'s business?

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

arrow icon

What is the price predicton of KRYS Stock?

Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Krystal Biotech Inc (KRYS)'s revenue for the last quarter?

Krystal Biotech Inc revenue for the last quarter amounts to 97.80M USD, increased 16.65 % YoY.

arrow icon

What is Krystal Biotech Inc (KRYS)'s earnings per share (EPS) for the last quarter?

Krystal Biotech Inc. EPS for the last quarter amounts to 2.66 USD, increased 192.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for Krystal Biotech Inc (KRYS)'s fundamentals?

The market is revising Upward the revenue expectations for Krystal Biotech, Inc. (KRYS) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 47.71%.
arrow icon

How many employees does Krystal Biotech Inc (KRYS). have?

Krystal Biotech Inc (KRYS) has 275 emplpoyees as of December 05 2025.

arrow icon

What is Krystal Biotech Inc (KRYS) market cap?

Today KRYS has the market capitalization of 6.31B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free